Piras Alessandra, Melis Giada, Cugusi Lucia, Bassareo Pier Paolo
Struttura Complessa di Cardiologia-UTIC-Emodinamica, Azienda Ospedaliero-Universitaria di Cagliari, 09042 Monserrato, Cagliari, Italy.
Pronto Soccorso ed OBI, Azienda Ospedaliero-Universitaria di Cagliari, 09042 Monserrato, Cagliari, Italy.
Pediatr Rep. 2022 Sep 26;14(4):401-409. doi: 10.3390/pediatric14040048.
One of the most powerful weapons against COVID-19 is vaccines. After the worldwide spread of the disease, m-RNA vaccines were authorized not only in adult patients, but also in children and adolescents aged 12-18. Since then, alarming reports of cases of myocarditis and/or pericarditis have been noted, primarily involving males after the second vaccine shot. A typical example of myopericarditis occurring in an adolescent a few days after the second shot of an m-RNA vaccine is described here. An in-depth review of all 110 single case reports published up to July 2022 with related features and outcomes is also presented. This is the first extensive analysis focused solely on a significant number of single case reports, which have usually been excluded from systematic reviews and meta-analyses carried out in the field. The analysis presented here confirms that most cases occurred in males after the second injection of an m-RNA vaccine. Cases were mild and responsive to the usual medical treatment. What is newly reported is that not only adolescents, but also older people, especially females, were affected by this adverse event.
对抗新冠病毒最有力的武器之一就是疫苗。在该疾病全球传播之后,信使核糖核酸(mRNA)疫苗不仅在成年患者中获得授权,在12至18岁的儿童和青少年中也得到授权。从那时起,就有令人担忧的心肌炎和/或心包炎病例报告,主要涉及第二次接种疫苗后的男性。本文描述了一名青少年在第二次接种mRNA疫苗几天后发生心肌心包炎的典型病例。本文还对截至2022年7月发表的110例具有相关特征和结果的单病例报告进行了深入综述。这是首次仅专注于大量单病例报告的广泛分析,这些单病例报告通常被排除在该领域进行的系统评价和荟萃分析之外。此处呈现的分析证实,大多数病例发生在第二次接种mRNA疫苗后的男性身上。病例症状较轻,对常规治疗有反应。新报道的情况是,不仅青少年,老年人尤其是女性也受到了这一不良事件的影响。